Lower Urinary Tract Symptoms in a Prospective Cohort of COVID-19 Survivors

Overview

Journal Int Braz J Urol

Specialty Urology

Date 2024 Mar 18

PMID 38498685

Authors

Cristiano M Gomes

Marcelo Hisano

Julia D Souza

Joao Victor T Henriques

Jose de Bessa Jr

Julyana Moromizato

Thulio Bosi

Rachel Mazoni

Joao Gismondi

Bruno Camargo

Zein M Sammour

Homero Bruschini

Linamara R Battistella

William C Nahas

Affiliations

Soon will be listed here.

Abstract

Purpose: To analyze the prevalence of lower urinary tract symptoms (LUTS) in patients who survived moderate and severe forms of COVID-19 and the risk factors for LUTS six months after hospitalization.

Materials And Methods: In this prospective cohort study, patients were evaluated six months after hospitalization due to COVID-19. LUTS were assessed using the International Prostate Symptom Score. General health was assessed through the Hospital Anxiety and Depression Scale and the EQ5D-L5 scale, which evaluates mobility, ability to perform daily activities, pain and discomfort and completed a self-perception health evaluation.

Results: Of 255 participants, 54.1% were men and the median age was 57.3 [44.3 - 66.6] years. Pre-existing comorbidities included diabetes (35.7%), hypertension (54.5%), obesity (30.2%) and physical inactivity (65.5%). One hundred and twenty-four patients (48.6%) had a hospital stay >15 days, 181 (71.0%) were admitted to an ICU and 124 (48.6%) needed mechanical ventilation. Median IPSS was 6 [3-11] and did not differ between genders. Moderate to severe LUTS affected 108 (42.4%) patients (40.6% men and 44.4% women; p=0.610). Nocturia (58.4%) and frequency (45.9%) were the most prevalent symptoms and urgency was the only symptom that affected men (29.0%) and women (44.4%) differently (p=0.013). LUTS impacted the quality of life of 60 (23.5%) patients with women more severely affected (p=0.004). Diabetes, hypertension, and self-perception of worse general health were associated with LUTS.

Conclusions: LUTS are highly prevalent and bothersome six months after hospitalization due to COVID-19. Assessment of LUTS may help ensure appropriate diagnosis and treatment in these patients.

Citing Articles

MRI and biopsy in prostate cancer are the hot topic in this number of International Brazilian Journal of Urology.

Favorito L Int Braz J Urol. 2024; 50(3):234-236.

PMID: 38598827 PMC: 11152325. DOI: 10.1590/S1677-5538.IBJU.2024.03.01.

References

Morin L, Savale L, Pham T, Colle R, Figueiredo S, Harrois A . Four-Month Clinical Status of a Cohort of Patients After Hospitalization for COVID-19. JAMA. 2021; 325(15):1525-1534. PMC: 7970386. DOI: 10.1001/jama.2021.3331. View

Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D . Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011; 20(10):1727-36. PMC: 3220807. DOI: 10.1007/s11136-011-9903-x. View

Barry M, Fowler Jr F, OLeary M, Bruskewitz R, HOLTGREWE H, MEBUST W . The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992; 148(5):1549-57; discussion 1564. DOI: 10.1016/s0022-5347(17)36966-5. View

Perez C, Michelutti L, Palharini M, Teixeira L, Silva V, Teixeira L . Interaction between the impact of the Coronavirus disease 2019 pandemic and demographic characteristics on sexual/erectile dysfunction in Latin America: cross-sectional study. Int Braz J Urol. 2022; 48(3):512-547. PMC: 9060173. DOI: 10.1590/S1677-5538.IBJU.2021.0764. View

Subramanian A, Nirantharakumar K, Hughes S, Myles P, Williams T, Gokhale K . Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med. 2022; 28(8):1706-1714. PMC: 9388369. DOI: 10.1038/s41591-022-01909-w. View

Daryanto B, Janardhana A, Purnomo A . The Effect of Covid-19 Severity on Lower Urinary Tract Symptoms Manifestations. Med Arch. 2022; 76(2):127-130. PMC: 9233460. DOI: 10.5455/medarh.2022.76.127-130. View

Creta M, Sagnelli C, Celentano G, Napolitano L, Rocca R, Capece M . SARS-CoV-2 infection affects the lower urinary tract and male genital system: A systematic review. J Med Virol. 2021; 93(5):3133-3142. PMC: 8013185. DOI: 10.1002/jmv.26883. View

Haghpanah A, Masjedi F, Salehipour M, Hosseinpour A, Roozbeh J, Dehghani A . Is COVID-19 a risk factor for progression of benign prostatic hyperplasia and exacerbation of its related symptoms?: a systematic review. Prostate Cancer Prostatic Dis. 2021; 25(1):27-38. PMC: 8129694. DOI: 10.1038/s41391-021-00388-3. View

Zachariou A, Sapouna V, Kaltsas A, Dimitriadis F, Douvli E, Champilomatis I . Evaluation of Overactive Bladder Symptoms in Patients Recovering from Post-Acute COVID-19 Syndrome. J Multidiscip Healthc. 2022; 15:2447-2452. PMC: 9618246. DOI: 10.2147/JMDH.S384436. View

10.

Busatto G, de Araujo A, Duarte A, Levin A, Guedes B, Kallas E . Post-acute sequelae of SARS-CoV-2 infection (PASC): a protocol for a multidisciplinary prospective observational evaluation of a cohort of patients surviving hospitalisation in Sao Paulo, Brazil. BMJ Open. 2021; 11(6):e051706. PMC: 8249176. DOI: 10.1136/bmjopen-2021-051706. View

11.

Korkes F, Smaidi K, Timoteo F, Glina S . Recommendations for prostate cancer diagnosis and treatment during COVID-19 outbreak were not followed in Brazil. Int Braz J Urol. 2022; 48(4):712-718. PMC: 9306370. DOI: 10.1590/S1677-5538.IBJU.2021.0673. View

12.

Selvi I, Irfan Donmez M, Ziylan O, Oktar T . Urodynamically proven lower urinary tract dysfunction in children after COVID-19: A case series. Low Urin Tract Symptoms. 2022; 14(4):301-304. PMC: 9115155. DOI: 10.1111/luts.12436. View

13.

Irwin D, Milsom I, Kopp Z, Abrams P, Artibani W, Herschorn S . Prevalence, severity, and symptom bother of lower urinary tract symptoms among men in the EPIC study: impact of overactive bladder. Eur Urol. 2009; 56(1):14-20. DOI: 10.1016/j.eururo.2009.02.026. View

14.

Lamb L, Dhar N, Timar R, Wills M, Dhar S, Chancellor M . COVID-19 inflammation results in urine cytokine elevation and causes COVID-19 associated cystitis (CAC). Med Hypotheses. 2020; 145:110375. PMC: 7644255. DOI: 10.1016/j.mehy.2020.110375. View

15.

Manganotti P, Michelutti M, Furlanis G, Deodato M, Buoite Stella A . Deficient GABABergic and glutamatergic excitability in the motor cortex of patients with long-COVID and cognitive impairment. Clin Neurophysiol. 2023; 151:83-91. PMC: 10170904. DOI: 10.1016/j.clinph.2023.04.010. View

16.

Damiano R, Caruso M, Cincoto A, Castanho de Almeida Rocca C, de Padua Serafim A, Bacchi P . Post-COVID-19 psychiatric and cognitive morbidity: Preliminary findings from a Brazilian cohort study. Gen Hosp Psychiatry. 2022; 75:38-45. PMC: 8734055. DOI: 10.1016/j.genhosppsych.2022.01.002. View

17.

Msemburi W, Karlinsky A, Knutson V, Aleshin-Guendel S, Chatterji S, Wakefield J . The WHO estimates of excess mortality associated with the COVID-19 pandemic. Nature. 2022; 613(7942):130-137. DOI: 10.1038/s41586-022-05522-2. View

18.

Andrade G, Sesconetto L, da Silva R, Santos G, Kayano P, Baccaglini W . Impact of COVID-19 pandemic on prostate cancer outcomes at an uro-oncology referral center. Int Braz J Urol. 2023; 49(2):233-242. PMC: 10247232. DOI: 10.1590/S1677-5538.IBJU.2022.0393. View

19.

Gomes C, Averbeck M, Koyama M, Soler R . Impact of OAB symptoms on work, quality of life and treatment-seeking behavior in Brazil. Curr Med Res Opin. 2020; 36(8):1403-1415. DOI: 10.1080/03007995.2020.1760806. View

20.

Tristao L, Bresler R, Modesto V, Fernandes R, Bernardo W . Urological complications of COVID-19: a systematic review. Int Braz J Urol. 2022; 49(1):24-40. PMC: 9881803. DOI: 10.1590/S1677-5538.IBJU.2022.0281. View